Actuate Therapeutics (NASDAQ: ACTU) shareholders back directors and ratify Crowe LLP as 2026 auditor
Rhea-AI Filing Summary
Actuate Therapeutics, Inc. held its virtual Annual Meeting of Stockholders on May 21, 2026. Stockholders elected two Class II directors, Aaron G.L. Fletcher, Ph.D. and Jason Keyes, each to serve three-year terms ending at the 2029 Annual Meeting, continuing until their successors are elected and qualified.
Fletcher received 14,877,247 votes for and 1,883,025 withheld, with 1,871,309 broker non-votes. Keyes received 16,727,875 votes for and 32,397 withheld, with 1,871,309 broker non-votes. Stockholders also ratified Crowe LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 18,571,817 votes for, 50,023 against, and 9,741 abstentions.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Votes for Fletcher: 14,877,247 votes
Votes withheld Fletcher: 1,883,025 votes
Votes for Keyes: 16,727,875 votes
+5 more
8 metrics
Votes for Fletcher
14,877,247 votes
Election of Aaron G.L. Fletcher, Ph.D. as Class II director
Votes withheld Fletcher
1,883,025 votes
Election of Aaron G.L. Fletcher, Ph.D.
Votes for Keyes
16,727,875 votes
Election of Jason Keyes as Class II director
Votes withheld Keyes
32,397 votes
Election of Jason Keyes
Broker non-votes directors
1,871,309 votes
Broker non-votes on each director election
Votes for auditor
18,571,817 votes
Ratification of Crowe LLP as auditor for 2026
Votes against auditor
50,023 votes
Ratification of Crowe LLP
Abstentions auditor
9,741 votes
Ratification of Crowe LLP
Key Terms
Annual Meeting of Stockholders, Class II director, broker non-votes, independent registered public accounting firm, +1 more
5 terms
Annual Meeting of Stockholders financial
"hosted its Annual Meeting of Stockholders (“Annual Meeting”) virtually"
Class II director financial
"elected each of the two Class II director nominees listed below"
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
broker non-votes financial
"Jason Keyes | 16,727,875 | 32,397 | 1,871,309"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"ratified the appointment of Crowe LLP as the Company's independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
emerging growth company regulatory
"Emerging growth company x"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did Actuate Therapeutics (ACTU) stockholders approve at the 2026 Annual Meeting?
Stockholders elected two Class II directors and ratified the company’s auditor. Aaron G.L. Fletcher, Ph.D. and Jason Keyes were elected to three-year terms, and Crowe LLP was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026.
How did Actuate Therapeutics (ACTU) stockholders vote on director Aaron G.L. Fletcher, Ph.D.?
Aaron G.L. Fletcher, Ph.D. received strong majority support. He obtained 14,877,247 votes for and 1,883,025 votes withheld, with 1,871,309 broker non-votes recorded, confirming his election as a Class II director for a term ending at the 2029 Annual Meeting.
What were the voting results for director Jason Keyes at Actuate Therapeutics (ACTU)?
Jason Keyes received broad stockholder support. He obtained 16,727,875 votes for and 32,397 votes withheld, along with 1,871,309 broker non-votes, resulting in his election as a Class II director through the 2029 Annual Meeting of Stockholders.
Which audit firm did Actuate Therapeutics (ACTU) stockholders ratify for 2026?
Stockholders ratified Crowe LLP as independent registered public accounting firm. The ratification received 18,571,817 votes for, 50,023 votes against, and 9,741 abstentions, covering the fiscal year ending December 31, 2026 for Actuate Therapeutics, Inc.
How many broker non-votes were recorded in Actuate Therapeutics’ (ACTU) director elections?
Both director elections recorded the same number of broker non-votes. For Aaron G.L. Fletcher, Ph.D. and Jason Keyes, there were 1,871,309 broker non-votes each, reflecting shares present but not voting on the director election proposals.
AI-generated analysis. How Rhea-AI works. Not financial advice.
